Last reviewed 2026-05-31 · How we verify

Ethazole (SULFAETHIDOLE)

Phase 2 active Small molecule ✓ Verified May 2026

Ethazole (generic name: SULFAETHIDOLE) is a sulfaethidole drug. It is currently in Phase 2 development.

Ethazole works by inhibiting the RAC-alpha serine/threonine-protein kinase enzyme, which plays a crucial role in cell signaling pathways.

Ethazole is a small molecule. It is also known by the synonyms SULFAETHIDOLE, SULFAETIDOL, and SUL-SPANSION.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULFAETHIDOLE
Drug class	sulfaethidole
Target	RAC-alpha serine/threonine-protein kinase
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of cell signaling like a messenger system. RAC-alpha serine/threonine-protein kinase is a key messenger that helps cells respond to their environment. By blocking this messenger, Ethazole can potentially disrupt abnormal cell growth and behavior.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ethazole CI brief — competitive landscape report
Ethazole updates RSS · CI watch RSS

Frequently asked questions about Ethazole

What is Ethazole?

Ethazole (SULFAETHIDOLE) is a sulfaethidole drug.

How does Ethazole work?

Ethazole works by inhibiting the RAC-alpha serine/threonine-protein kinase enzyme, which plays a crucial role in cell signaling pathways.

What is the generic name of Ethazole?

SULFAETHIDOLE is the generic (nonproprietary) name of Ethazole.

What drug class is Ethazole in?

Ethazole belongs to the sulfaethidole class. See all sulfaethidole drugs at /class/sulfaethidole.

What development phase is Ethazole in?

Ethazole is in Phase 2.

What does Ethazole target?

Ethazole targets RAC-alpha serine/threonine-protein kinase and is a sulfaethidole.

Drug class: All sulfaethidole drugs
Target: All drugs targeting RAC-alpha serine/threonine-protein kinase
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing